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Background. Liver regeneration is of crucial importance for patients undergoing living liver transplantations or
extended liver resections and can be associated with elevated portal venous pressure, impaired hepatic regeneration,
and postoperative morbidity. The aim of this study was to assess whether reduction of portal venous pressure by
terlipressin improves postoperative liver regeneration in normal and steatotic livers after partial hepatectomy in a
rodent model.
Methods. Portal venous pressure was assessed after minor (30%), standard (60%), or extended (80%) partial hep-
atectomy (PH) in mice with and without liver steatosis. Liver regeneration was assessed by BrdU incorporation and
Ki-67 immunostaining.
Results. Portal venous pressure was significantly elevated post-PH in mice with normal and steatotic livers compared
to sham-operated mice. Reduction of elevated portal pressure after 80% PH by terlipressin was associated with an
increase of hepatocellular proliferation. In steatotic livers, animals treated with terlipressin had an increase in liver
regeneration after 30% PH and increased survival after 60% PH. Mechanistically, terlipressin alleviated IL-6 mRNA
expression following PH and down-regulated p21 and GADD45 mRNA suggesting a reduction of cell cycle inhibition
and cellular stress.
Conclusions. Reduction of elevated portal pressure post-PH by the use of terlipressin improves liver regeneration
after PH in lean and steatotic mouse livers.
Keywords: Liver regeneration, Portal hypertension, Partial hepatectomy, Liver steatosis, Terlipressin.
(Transplantation 2014;97: 892Y900)
O ptimal liver regeneration is of crucial relevance for thepatient undergoing living liver donation and transplan-
tation and liver resection. Removal of significant propor-
tions of liver parenchyma is associated with an increase of
portal blood flow and pressure (1Y3). It has been shown that
portal blood flow and pressure is increased immediately after
partial hepatectomy (PH) and triggers various signaling path-
ways (4, 5). However, the optimal range of portal blood flow
and portal venous pressure required for best parenchymal
regeneration after PH remains to be defined. Until now, the
only options that are clinically used to improve liver regen-
eration are invasive interventions such as preoperative embo-
lization of portal vein branches (6, 7), splenic artery ligation
(8, 9), splenectomy, or shunt operations (2, 10). However, de-
spite their efficacy, these procedures are associated with addi-
tional surgical risks and potential morbidity.
The aim of this study was to explore whether pharma-
ceutical modulation of portal venous pressure in a non-cirrhotic
liver optimizes liver regeneration and improves outcome after
PH. Terlipressin, a synthetic analog of vasopressin, effectively
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reduces portal venous pressure in patients with liver cirrhosis
and is currently recommended to lower portal venous pres-
sure in the treatment of variceal bleeding and hepatorenal
syndrome (11, 12).
Terlipressin acts as a vasoconstrictor via activation of
vasopressin-1 receptors located in the smooth muscles of the
arterial vasculature in the splanchnic region and thus de-
creases mesenteric and hepatic blood flow (13). A recent study
proposed that terlipressin improves renal function and de-
creases portal venous pressure in patients undergoing dona-
tion for living-donor liver transplantation (14). However, no
data on whether these circulatory effects impact liver paren-
chymal regeneration after PH are currently available.
Patients undergoing liver surgery with liver steatosis are
an increasing problem in Western countries as liver steatosis
is associated with an increased risk for postoperative compli-
cations (15, 16) and delayed liver regeneration in patients
undergoing hepatic resection (17). In liver transplantation, ele-
vated liver steatosis results in an increased graft failure (18).
Thus, hepatic steatosis that is associated with reduced func-
tional capacity is of crucial clinical relevance. Therefore, the
impact of terlipressin on portal venous pressure and liver re-
generation post-PH was also evaluated in mice with and
without steatosis.
The present study shows that terlipressin reduces portal
venous pressure and improves outcome after extended PH
in lean and steatotic livers. This effect is accompanied by im-
proved liver cell regeneration mediated via the inhibition of
proteins associated with cell cycle inhibition (p21) and cellular
stress (GADD45) and modulation of interleukin (IL)-6 levels.
RESULTS
Portal Venous Pressure is Modulated After PH
in Response to Terlipressin
In mice that underwent 30% (minor), 60% (standard),
or 80% (extended) PH, portal venous pressure positively corre-
lated with the extent of liver resection with the highest pressure
FIGURE 1. Invasive measurements of portal venous pressure before and after PH. A, portal venous pressure positively
correlates with the extent of PH in mice after 30%, 60%, and 80% PH (Student t test). B, after 30% PH, portal venous
pressure remained significantly elevated in both groups compared to baseline with insignificant higher levels after ter-
lipressin administration probably as a result of the mechanism of vasoconstriction of terlipressin (P=0.2). C, portal venous
pressure did not differ after 60% PH between PBS- and terlipressin-treated animals (P=0.5). D, after 80% PH, terlipressin
administration was associated with significantly decreased portal venous pressure compared to controls over time
(PG0.001). E, after administration of terlipressin or PBS, portal venous pressure is not significantly different over time
(P=0.7). Animals n=8 per group and extent of PH. Mean, bars=SEM, two-way ANOVA test in (B) to (E).
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levels observed after 80% PH (Fig. 1A). Terlipressin signifi-
cantly decreased portal venous pressure in mice after 80%,
but not after 30% and 60% PH compared to vehicle controls
(Fig. 1BYD). Administration of terlipressin in sham-operated
animals did not alter portal venous pressure (Fig. 1E).
Liver Regeneration After 80% PH is Increased
in Response to Terlipressin
Hepatocellular proliferation was used as a surrogate of pa-
renchymal regeneration and was assessed by BrdU incorporation
(Fig. 2A and B) and Ki-67 immunostaining (Fig. 2C and D)
FIGURE 2. Immunohistochemical analysis with BrdU and Ki-67 staining after 48 hr post-PH. A, C, significant increase
of positive cells after terlipressin administration with 80% PH compared to controls. B, D, representative liver sections
of immunohistochemistry analysis of BrdU and Ki-67-positive hepatocytes. Assessment of liver injury by serum AST (E) and
ALT (F) levels after 8 hr post-PH. Horizontal lines indicate mean, Student t test.
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48 hr after PH. Mice subjected to 30% and 60% PH had
substantial liver regenerative activity, which was not further in-
creased by the administration of terlipressin. However, hepa-
tocellular proliferation after 80% PH was significantly enhanced
in response to terlipressin. Serum transaminases (aspartate
transaminase [AST] and alanine aminotransferase [ALT]) in-
creased in accordance with the extent of PH, reflecting hepa-
tocyte injury, but there was no relevant difference between
animals treated with terlipressin compared to vehicle controls
(Fig. 2E and F). Histology revealed no differences in terms of
liver injury between the two treatment groups after 80% PH
(Fig.S1AYFandFig.S2AYF,SDC,http://links.lww.com/TP/A948).
An increase of microsteatotic changes and cell ballooning was
seen with a maximum after 24 hr after PH without changes
after terlipressin administration. Histomorphology revealed
foci of slight hepatocellular enlargement in lobular zone two.
However, there were no differences between the mice treated
with terlipressin and the control group. In addition, no elevation
FIGURE 3. Expression of hepatic mRNA of (A) IL-6 and (B) GADD45 30 min post-PH and (C) p21 after 24 hr assessed by
quantitative RT-PCR were significantly increased after 80% PH in comparison to 60% PH in control animals. After
terlipressin treatment, protein levels after 80% PH decreased significantly, whereas after 60% PH there were no significant
changes. D, serum bile acid levels by ELISA after 48 hr post-PH. Electron microscopy of liver sinusoids 4 hr post-PH. After
PBS administration and 80% PH (E), more disruption and destruction of sinusoids membrane was observed (arrow) com-
pared to terlipressin administration (F). Mean, bars=SD, Student t test.
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of hepatocellular proliferation was visible in sham-operated
mice after terlipressin administration (data not shown).
Modulation of Cytokine and Stress Responses
The expression of proteins associated with a cytokine
response (IL-6), cellular stress (GADD45), and cell cycle inhibition
(p21) were examined post-PH with and without terlipressin.
Expression of hepatic IL-6 mRNA was significantly lower post-
terlipressin administration compared to controls after 80% PH
but not after 60% (Fig. 3A). Proteins associated with cellular
stress in response to partial hepatectomy, such as GADD45,
and cell cycle inhibition, such as p21, were significantly de-
creased in animals treated with terlipressin compared to ve-
hicle controls after 80% but not after 60% PH (Fig. 3B and C).
The significant differences occurred at 30 min post-PH for
IL-6 and GADD45 and after 8 and 24 hr for p21 (Fig. S3 AYC,
SDC, http://links.lww.com/TP/A948). An increase of serum
bile acid levels as a marker of excretory biliary function post-
PH (19) was seen with the extent of PH in both treatment
groups (Fig. 3D). Administration of terlipressin was associ-
ated with a significant decrease of bile acid levels in mice only
after 80% PH (P=0.03) but not in 30% or 60% PH. Electron
microscopy revealed that the hepatic sinusoids were markedly
disrupted after 80% PH (Fig. 3E). Staining for sinusoidal
endothelial cells by CD31 revealed no significant differences
between control and terlipressin-treated animals (Fig. S4 AYF,
SDC, http://links.lww.com/TP/A948). However, by electron
microscopy there was reduced disruption of endothelial cell
damage in terlipressin-treated animals, suggesting that terlipres-
sin protects the liver from microstructural sinusoidal damage
caused by 80% PH (Fig. 3F).
Portal Venous Pressure, Survival, and Liver
Regeneration After PH in Liver Steatosis
The effect of terlipressin on portal venous pressure, liver
regeneration, and survival was explored in mice with steatotic
livers. After 6 weeks on a high-fat diet (HFD), mice developed
liver steatosis with a significant increase of liver weight but with-
out changes in total body weight compared to control animals
(Fig. 4A and B). Levels of tumor necrosis factor (TNF)->, p21,
and GADD45 mRNA were significantly increased in mice with
HFD compared to mice receiving standard chow indicating
lipotoxicity from fat deposits in the liver, whereas IL-6 tran-
scripts were significantly lower in mice with steatosis com-
pared to mice with normal liver parenchyma (Fig. 4CYF).
Steatotic changes and accumulation of intracellular fat droplets
FIGURE 4. Comparison of mice fed a high fat diet (HFD) versus control diet. A, HFD for 6 weeks showed no effect on
whole body weight. B, HFD was associated with a significant increase of liver weight. Expression of mRNA of (C) TNF alpha,
(D) IL-6, (E) GADD45, and (F) p21 in liver tissues of lean and steatotic livers (HFD). Mean, bars=SD, Student t test.
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FIGURE 5. Effect of terlipressin treatment on portal venous pressure, liver regeneration, and liver injury after PH in
animals treated with high-fat diet (HFD). A, B, portal venous pressure after 30% and 60% PH. Mean, bars=SEM, two-way
ANOVA test. C, D, assessment of proliferation by BrdU and Ki-67 immunostaining after 48 hr after 30% PH. E, F, no effect
of terlipressin on liver injury assessed by AST and ALT levels 8 hr after 30% PH. G, serum bile acid levels measured by
ELISA after 48 hr after 30% PH. Mean, bars=SD, Student t test. H, significant improvement of survival after treatment with
terlipressin after 60% PH. Kaplan-Meier survival curve, log rank.
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were not associated with an increase of basal portal venous
pressure or hydroxyproline content of the liver, thereby ex-
cluding significant hepatic fibrosis in this model (Fig. S5 AYD,
SDC, http://links.lww.com/TP/A948). These findings were
confirmed by liver histology and revealed slight changes as
hepatocellular degradation, cell ballooning, and mild in-
flammatory infiltrates, but no significant fibrosis (Fig. S5 E
and F, SDC, http://links.lww.com/TP/A948). Administra-
tion of terlipressin in mice with liver steatosis was associ-
ated with decreased portal venous pressure after 30% PH
(Fig. 5A) and 60% PH (Fig. 5B) compared to vehicle-
treated controls. Terlipressin significantly increased hepat-
ic proliferation 48 hr after 30% PH (Fig. 5C and D), whereas
it had no effect on liver injury as assessed by AST and ALT
levels in 30% and 60% PH (Fig. 5E and F). Additionally,
there were no significant changes in bile acid levels after
48 hr after 30% PH and HFD (Fig. 5G). For survival anal-
ysis, all animals were included that were enrolled for the
48-hr proliferation measurements. In mice with liver steatosis,
survival was significantly lower after 60% PH compared to
control mice without HFD (P=0.01), and administration of
terlipressin was associated with a significantly improved sur-
vival (58% vs. 30% after 50 hr; P=0.046; Fig. 5H).
DISCUSSION
The data presented in this study provide evidence that
elevated portal venous pressure following PH can be reduced
by a pharmacological approach and improves parenchymal
regeneration in mice. Importantly, terlipressin improved he-
patocellular proliferation in mice after 80% hepatectomy and
increased survival in mice with liver steatosis indicating a
therapeutic potential for terlipressin in situations with a high
risk of postoperative liver insufficiency. Mechanistically, hepato-
protection from terlipressin may be explained by reduced cellu-
lar stress as reflected by decreased levels of p21 and GADD45
and altered cytokine response. Interestingly, terlipressin modu-
lated regeneration but had no effect on liver injury.
An increase in portal venous pressure correlated with
the extent of PH and was detected immediately following
resection of liver lobes. Minor elevations of portal venous
pressure after PH have been shown to be pivotal for the
initiation of liver regeneration (20). Conversely, extended
liver resections or small-for-size liver transplantations that
are associated with a marked increase of portal venous
pressure, beyond yet undefined levels, may impair the re-
generative capacity of the liver and lead to liver failure (21).
To be clinically applicable and to avoid side effects in ani-
mals with normal portal venous pressure, the administra-
tion of the drug was performed immediately after PH.
Therefore, the very first elevation of portal venous pressure
was not altered. Despite this delayed injection, a positive
effect on liver regeneration and reduced cellular stress after
80% PH has been observed. The reduction of portal venous
pressure at 8 hr post-PH reflects early changes of hepatic
remodeling and adaptation of the sinusoids to the alter-
ations of pressure and flow in response to PH (22). Thus,
maintaining optimal levels of postoperative portal venous
pressure seems to be crucial for successful outcomes.
Administration of terlipressin was only protective after
80% PH. Thus, nonsignificant changes in portal venous
pressure after 60% PH after treatment with terlipressin are
not sufficient to impact on liver regeneration. This finding is
supported by increasing evidence that not the size alone but
the flow in resected or transplanted livers play an important
role in liver regeneration and ‘‘small for flow’’ rather than
‘‘small for size’’ seems to be critical (23).
Our report now shows for the first time that modu-
lation of portal venous pressure by terlipressin is beneficial
in the absence of liver cirrhosis. Up to now, vasopressin
agonists have been shown to be clinically effective in lower-
ing portal venous pressure in cirrhotic livers and terlipressin
has been shown to improve short-term survival of patients
with hepatorenal syndrome (24). Interestingly, a reduction of
portal venous pressure by terlipressin occurs only after 80%
PH that critically impact not just on portal venous pressure
but also on splanchnic blood flow and systemic metabolism
(25). The impact of physiological release of vasopressin on
liver regeneration via Ca2+ signaling has been previously
described (5, 26). These reports have shown neuroendocrine
secretion of vasopressin from the hypothalamus in response
to PH that protects the liver. We now support these mecha-
nistic findings at the target organ and show that pharmaco-
logical activation of vasopressin receptors reduces portal
venous pressure and is associated with an increase in liver
regeneration.
There is little evidence whether terlipressin has direct
stimulative potential on hepatocyte proliferation. No effect
of terlipressin on hepatocellular proliferation or on portal
venous pressure has been observed after minor or standard
PH. Thus, the main pathway of inducing hepatocyte pro-
liferation is probably by means of lowering the portal ve-
nous pressure and consecutive reduced cellular stress rather
than via direct hepatocyte V1a vasopressin receptors.
Terlipressin mainly acts through a vasoconstriction in
the splanchnic vessels and therefore reduces the portal flow
and portal venous pressure in cirrhosis and consecutive
splanchnic vasodilatation. Hypothetically, terlipressin also
counteracts a potential hepatic buffer response that may occur
post-PH. The doses of terlipressin used in this study were
comparable to previous reports in cirrhotic mice with effec-
tive reduction of portal pressure mainly after 80% PH and
without negative side effects on, for example, intestinal per-
fusion. In patients undergoing living liver transplantation,
terlipressin administration was associated with an effective
reduction of portal venous pressure and improvement of renal
function without having negative systemic side effects (14).
Hepatic steatosis is a frequent parenchymal liver dis-
ease in Western countries. Liver transplantation of livers
with modest steatosis is a potential clinical scenario, and it
has been shown clinically and experimentally that it is as-
sociated with an increased risk for complications (15, 27).
There was no mortality after 80% PH, but after 60% PH in
steatotic mice. Thus, a blunted response to this critical ex-
tent of PH may explain the effect of terlipressin at 60% PH
in steatotic mice.
In addition to the hemodynamic changes in response
to terlipressin administration, we demonstrated reduced
cellular stress (GADD45) and cell cycle inhibition (p21) af-
ter 80% PH. Both parameters were already significantly up-
regulated in steatotic livers before surgery, which explains
the effect already at 60% PH. These results confirm recent
studies that demonstrated a critical impact of both p21 and
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GADD45 on the initiation and the kinetics of liver regen-
eration (28Y30).
Our study also revealed that terlipressin reduced dis-
ruptions of hepatic sinusoids, which were associated with
extended PH. As previously shown in a transgenic animal
model, portal hypertension is associated with a morpho-
logical change of sinusoidal fenestrations, and PH is char-
acterized by a disappearance of the sieve-plate arrangement,
endothelial fenestration, and dilatation of bile canaliculi
(31, 32). The sinusoidal disruption as observed in the pres-
ent study is potentially associated with an increased intrahepatic
blood shunting between portal venous and systemic circulation.
Therefore, metabolites of the liver such as bile acids might be
found in higher concentrations in the systemic blood circu-
lation because of increased blood shunting after extended PH.
It remains unclear if coincidence of reduced bile acids and
reduced sinusoidal disruption in response to terlipressin ad-
ministration is the consequence or the cause of improved
outcome for the liver regeneration.
In summary, our results show pharmacological reduc-
tion of portal venous pressure with terlipressin leads to an
improvement of liver regeneration, maintenance of micro-
structural hepatic tissue anatomy, a reduction of stress response
genes, and, most importantly, a better survival.
MATERIALS AND METHODS
All procedures were carried out in accordance with the Swiss National
Institutes of Health guidelines for the care and use of experimental animals,
and the experimental protocol received approval by the Animal Care
Committee of the Canton of Bern, Switzerland.
Animal Preparation and Experimental Setting
Experiments were performed on 8- to 12-week-old adult wild-type
C57BL/6J mice obtained from Harlan Animal Research Laboratories
(Boxmeer, The Netherlands). The animals were housed in the University
Animal Facility with a 12 hr light/dark cycle at 22-C, and fed either with
normal chow (fat: 4.5%, protein: 18.5%, fibers: 4.5%) or with a high-fat diet
(Ssniff, Soest, Germany) for 6 weeks (HFDVfat: 16.6% [50% lard and 50%
cacao butter], protein: 15.7%, fibers: 4.5%). Surgical procedures were per-
formed under general anesthesia using isoflurane (Nicholas Piramal (I)
Limited, London, UK). During the procedure, the intestine was rinsed with
saline to avoid drying-out and resuscitation with saline of the intraoperative
fluid loss was given at the end of the operation. Postoperative analgesia with
buprenorphin (Reckitt Benckiser AG, Switzerland) was regularly administered
subcutaneously during the postoperative course. At the time of sacrifice, mice
were anesthetized with isoflurane inhalation, lethal blood samples were taken
from the inferior vena cava, and livers were collected for further analyses.
Partial Hepatectomy Model and Treatment
With Terlipressin
The details of the PH model in mice were previously published (33). In
brief, resection of the median and left lobe equals a standard 60% PH,
whereas for minor PH (30%) only the left superior lobe was excised. For
extended PH (80%), the right inferior lobe was resected in addition to the
standard 60% PH. Directly after performing PH and before closure of the
abdomen, the animals received terlipressin (0.05 Kg/g mouse, Glypressin;
Ferring Pharmaceuticals, Switzerland) or the vehicle phosphate-buffered
saline (PBS; Gibco, Invitrogen, Auckland, New Zealand) as control (5 KL/g
mouse) intravenously injected into the inferior vena cava. After 8 hr, this
administration was repeated by injections into the femoral vein under general
anesthesia with isoflurane. Two hours before sacrifice, 50 mg/kg mouse of bro-
modeoxyuridine (BrdU, #16880; Fluka, Sigma Aldrich, Switzerland) was injected
intraperitoneally. For each extent of PH with or without HFD, there was a
treatment and control group of each 8 to 12 animals per group and time point.
Measurement of Portal Venous Pressure
Portal venous pressure measurements were terminal experiments and
were not used for survival analysis. After laparotomy the ileocecal vein was
identified and a 26 G catheter was inserted and the catheter tip placed close
to the portal confluence and finally fixed with histoacryl. Baseline portal
venous pressure was measured by a computer-based program (FlowChart
7.0; AD Instruments, Spechbach, Germany) during 1 min. Portal venous
pressure was measured at specific time points before and after (5, 10, 15, 30 min
and 8 hr) PH and always required anesthesia and laparotomy.
Histological and Immunohistochemical
Analysis of the Liver
Fresh liver tissue was fixed overnight in 4% paraformaldehyde in PBS
and embedded in paraffin. Liver sections (5 Km) were deparaffinized with
xylol and counterstained with hematoxylin-eosin and with reticulin stain
(Ag) for histological assessment. For immunohistochemistry, paraffin-embedded
tissue sections were dried for 24 hr, deparaffinized, and rehydrated, followed
by blocking of endogenous peroxidase with 3% H2O2 (Sigma H-1009; Sigma-
Aldrich Chemie GmbH, Steinheim, Germany) in PBS. Antigen was retrieved
by heating the slides for 10 min. Diluted biotinylated anti-BrdU antibody
(BrdU In-Situ Detection Kit [#550803]; BD Biosciences, San Diego, CA) or
anti-Ki-67 antibody (Ki-67 clone-Tec 3 [#M7249]; Dako, Glostrup, Denmark)
were then applied and slides incubated for 1 hr at 48-C in a humidified
chamber. Then, ready-to-use streptavidin horseradish peroxidase complex
(#550803; BD Biosciences) was added, followed by a brief incubation with
3,3¶-diaminobenzidine substrate (DAB, D-4293, Sigmafast; Sigma-Aldrich
Chemie GmbH). The tissue sections were counterstained in hematoxylin.
Finally, BrdU and Ki-67-positive cells on representative slides were counted
on four high-power fields for each animal.
For CD31 staining, 2- to 3-Km liver sections were dewaxed, rehydrated,
and pretreated by boiling in 10 mM citrate buffer, pH 6.0, in a microwave
oven. Endogenous peroxidase activity was blocked with 0.5% H2O2 and
0.1% NaN3. Sections were then (and following all subsequent steps) washed
in Tris-buffered saline (TBS) and incubated for 60 min at room tempera-
ture with a rat-anti-mouse CD31 antibody (clone MEC 14.7; Abcam,
Cambridge, UK), diluted 1:100 in TBS with 0.5% casein and 5% normal
goat serum. In negative controls, the primary antibody was replaced with
antibody dilution buffer. A rabbit-anti-rat Ig secondary antibody (Dako) was
then applied, followed by a polymer-based visualization system (Envision+;
Dako), each for 30 min. Finally, sections were developed in 0.02% 3,3¶-
diaminobenzidine (Sigma, St. Louis, MO) with 0.01% H2O2, counterstained
with hematoxylin, and mounted. Known positive controls were stained in
parallel with each series.
To visualize liver steatosis, cryosections of 8-Km thickness from liver
tissue frozen immediately after removal at j120-C were fixed in 4% para-
formaldehyde. After dipping in 70% ethanol, sections were placed in Sudan
Black solution for 20 min and rinsed afterwards in 70% ethanol and H2O.
Finally, sections were stained with nuclear fast red vector (H-3403; Sigma-
Aldrich Chemie GmbH).
Measurement of Liver Injury
ALT and AST levels were measured by a photometric UV test measuring
the oxidation of NADH to NAD (Roche Modular P800). Bile acids levels in
the serum after 48 hr post-PH were measured enzymatically using a Mira
plus chemistry analyzer (Roche Diagnostics) with reagents from Trinity
Biotech as previously described (34). Briefly, during oxidation of the bile
acids to 3-oxo bile acids, equimolar quantity of NAD is reduced to NADH,
which subsequently is oxidized to NAD. Nitroblue tetrazolium salt is then
reduced to formazan, which has an absorbance maximum at 530 nm. The
concentration of bile acids in the sample is directly proportional to the
intensity of the produced color.
Hydroxyproline
Quantification of hepatic hydroxyproline was measured as previously
described (35). Briefly, after hydrolyzation of frozen liver tissue in 6 M HCl
at 100-C for 16 hr, 50 KL was incubated with chloramine T (2.5 mM) for
5 min and Ehrlich reagent (410 mM) for 30 min at 60-C. Finally, absorption
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at 560 nm was measured and results expressed as micrograms per gram of
wet liver tissue.
Quantitative TaqMan PCR
RNA was isolated from snap-frozen liver samples by Trizol Reagent
according to the manufacturer’s protocol (Life Technologies). cDNA was
synthesized by using Omniscript RT kit 200 (cat. no. 205113; Qiagen) and
mRNA analyzed by RT-qPCR (ABI 7900, SDS 2.3 software). Primers and
probes sequences were ready-to-use kits from Applied Biosystems (Rotkreutz,
Switzerland), reference gene control (RG) beta actin (#Mm00607939_s1), IL-6
(#Mm00446190_m1), TNF-> (#Mm00443258_m1), GADD45 (#Mm00432802_m1),
and CDKN1a (=p21) (#Mm00432448_m1). Relative changes in mRNA were
calculated with the $$$Ct method. Ct values of target gene expression (TG)
was calculated relative to a RG using the following formula $CtTG=CtTGjCtRG.
Experimental groups (TG) were normalized to control group (CG): $$Ct=
$CtTGj$CtCG, fold increase=2
j$$Ct.
Transmission Electron Microscopy
To assess a putative effect of terlipressin treatment on hepatic sinusoids,
respective cellular structures liver tissues were imaged by transmission
electron microscopy. For that, liver samples were fixed in 5% glutaraldehyde
in PBS, postfixed in osmium tetroxide, stained en bloc in uranyl acetate,
dehydrated, and embedded in epoxy resin. Ultrathin sections (50Y100 nm)
were analyzed with an EM12 transmission electron microscope (Philips,
Eindhoven, Netherlands) equipped with a digital camera (Morada; SIS,
Mu¨nster, Germany). Sinusoidal structures were analyzed blinded by an
experienced liver pathologist (M.M.) for ultrastructural changes.
Statistics
All data are expressed as geometric meansTstandard deviations unless
stated otherwise. For statistical analysis, Student t test or two-way ANOVA
test was used. Statistical analysis was performed with GraphPad Prism
version 5.0 (GraphPad Software, Inc., La Jolla, CA). Data with P less than
0.05 was considered as statistically significant.
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